Dejnek M, Witkowski J, Moreira H, Płaczkowska S, Morasiewicz P, Reichert P, Królikowska A. Content of blood cell components, inflammatory cytokines and growth factors in autologous platelet-rich plasma obtained by various methods. World J Orthop 2022; 13(6): 587-602 [PMID: 35949706 DOI: 10.5312/wjo.v13.i6.587]
Corresponding Author of This Article
Maciej Dejnek, MD, Research Scientist, Surgeon, Department of Trauma Surgery, Wroclaw Medical University, ul. Borowska 213, Wroclaw 50-556, Poland. maciej.dejnek@student.umed.wroc.pl
Research Domain of This Article
Sport Sciences
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Orthop. Jun 18, 2022; 13(6): 587-602 Published online Jun 18, 2022. doi: 10.5312/wjo.v13.i6.587
Table 1 The main characteristics of the platelet-rich plasma protocols used in the study
Arthrex ACP
Mini GPS III
Xerthra
Dr. PRP
Amount of blood collected
13.5 mL
27 mL
13.5 mL
18 mL
Final amount of PRP
4 mL
3 mL
1.5 mL
3 mL
Drawn blood/obtained PRP
3.38:1
9:1
9:1
6:1
Anticoagulant type
ACD-A
ACD-A
3.13% SOD CITR
3.13% SOD CITR
Anticoagulant amount
1.5 mL
3 mL
1.5 mL
2 mL
Number of spins
1
1
1
1
RPM
1500
3200
3500
3100
Centrifugation time
5’
15’
5’
4’
Removal of PPP
no
yes
yes
yes
Expected WBC content
low
high, 5x
low
low
Expected PLT concentration
2-3 x
9.3 x
2-13 x
4-5 x
Dedicated centrifuge
Yes
Yes
Yes
Yes
Activation method
In vivo
In vivo
In vivo
In vivo
Type of PRP
Conditioned Plasma
LR-PRP
LP-PRP
LP-PRP
Table 2 Whole blood count with differential leukocyte of all participants
Differential leukocyte
Blood count
RBC (1012/L)
4.97 ± 0.43
PLT (109/L)
240.67 ± 49.85
WBC (109/L)
6.49 ± 1.49
Neutrophils (109/L)
3.79 ± 1.29
Lymphocytes (109/L)
2.08 ± 0.45
Monocytes (109/L)
0.45 ± 0.13
Eosinophils (109/L)
0.14 ± 0.08
Basophils (109/L)
0.04 ± 0.01
Table 3 Concentrations of blood cell components in platelet-rich plasma samples
Arthrex ACP
Mini GPS III
Xerthra
Dr. PRP
PLT (109/L)
357.33 ± 99.01
1212.67 ± 268.63
455.27 ± 362.92
499.75 ± 153.46
WBC (109/L)
0.87 ± 1.01
34.19 ± 11.18
1.80 ± 2.55
0.60 ± 0.87
Neutrophils (109/L)
0.87 ± 1.01
16.71 ± 9.89
1.80 ± 2.55
0.60 ± 0.87
RBC (1012/L)
0.05 ± 0.08
1.49 ± 0.86
0.02 ± 0.02
0.01 ± 0.01
xPLT
1.47 ± 0.18
5.05 ± 0.67
1.96 ± 1.71
2.14 ± 0.73
xWBC
0.14 ± 0.17
5.27 ± 1.41
0.29 ± 0.4
0.10 ± 0.16
xRBC
0.01 ± 0.02
0.30 ± 0.17
0.00
0.00
Table 4 The coefficient of variation in the concentration of blood cell components for different platelet-rich plasma preparation systems
WBC
RBC
PLT
Arthrex ACP [%]
114.80
175.69
12.18
Mini GPS III [%]
26.79
56.83
13.25
Xerthra [%]
149.38
133.98
95.95
Dr. PRP [%]
151.45
95.10
34.05
Citation: Dejnek M, Witkowski J, Moreira H, Płaczkowska S, Morasiewicz P, Reichert P, Królikowska A. Content of blood cell components, inflammatory cytokines and growth factors in autologous platelet-rich plasma obtained by various methods. World J Orthop 2022; 13(6): 587-602